☆ 4.6 Article

COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials

NATURE REVIEWS CLINICAL ONCOLOGY (2021)

Related references

Note: Only part of the references are listed.

Letter Oncology

Commentary: SARS-CoV-2 vaccines and cancer patients

C. Corti et al.

ANNALS OF ONCOLOGY (2021)

Add to Collection

Review Oncology

Mortality in hospitalized patients with cancer and coronavirus disease 2019: A systematic review and meta-analysis of cohort studies

Aakash Desai et al.

Summary: The analysis of 2922 cancer patients with COVID-19 from primarily inpatient studies showed a 30-day mortality rate of 30%, while the overall rate was 15% among 624 patients from studies including both inpatient and outpatient populations. Factors such as male sex, older age, cancer subtype, and recent active cancer therapy partially explained the heterogeneity in mortality reporting, with male sex and an interaction between patient age and recent therapy accounting for most of the variance in mortality rates between studies.

CANCER (2021)

Add to Collection

Article Medicine, General & Internal

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Merryn Voysey et al.

Summary: The ChAdOx1 nCoV-19 vaccine has been shown to have an acceptable safety profile and effectiveness against symptomatic COVID-19, with higher efficacy observed in the group that received a low dose followed by a standard dose.

LANCET (2021)

Add to Collection

Article Oncology

High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib

Tiziano Barbui et al.

Summary: The study found a high risk of mortality among MPN patients during COVID-19 infection, especially in MF patients and those discontinuing Ruxo treatment. Further investigation is needed on the role of Ruxo treatment and its interruption in affecting mortality in MPN patients with COVID-19.

LEUKEMIA (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Looking beyond COVID-19 vaccine phase 3 trials

Jerome H. Kim et al.

Summary: Following the announcement of COVID-19 vaccine efficacy in clinical trials, a comprehensive strategy is needed for global vaccination, including manufacturing, support, supply coordination, equitable distribution, and logistics. Additionally, addressing scientific questions to improve vaccine efficacy is crucial for ending the pandemic effectively and efficiently.

NATURE MEDICINE (2021)

Add to Collection

Article Oncology

Priority COVID-19 Vaccination for Patients with Cancer while Vaccine Supply Is Limited

Antoni Ribas et al.

Summary: Patients with cancer, especially those with hematologic malignancies, are considered among the very high-risk groups for priority COVID-19 vaccination due to the confluence of risk factors between cancer and the virus, which may increase exposure and suppress immune responses.

CANCER DISCOVERY (2021)

Add to Collection

Article Hematology

Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study

Akshay Sharma et al.

Summary: This study examined the characteristics and outcomes of HSCT recipients after developing COVID-19. It found that recipients of autologous and allogeneic HSCT who develop COVID-19 have poor overall survival rates. Factors such as age, sex, and time since transplantation were associated with higher risk of mortality in HSCT recipients.

LANCET HAEMATOLOGY (2021)

Add to Collection

Letter Oncology

Association of the COVID-19 Outbreak With Patient Willingness to Enroll in Cancer Clinical Trials

Mark E. Fleury et al.

Summary: This study focuses on the attitudes of cancer survivors towards participation in clinical trials during the COVID-19 outbreak.

JAMA ONCOLOGY (2021)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

Management of Unilateral Axillary Lymphadenopathy Detected on Breast MRI in the Era of COVID-19 Vaccination

Christine E. Edmonds et al.

Summary: Early clinical experience indicates that approved COVID-19 vaccines may lead to higher rates of axillary lymphadenopathy compared to other vaccines on breast MRI. Guidelines are necessary to manage unilateral axillary lymphadenopathy detected by MRI in the context of COVID-19 vaccination, helping to prevent unnecessary biopsies of benign reactive nodes. Institution-specific strategies, such as adding questions about COVID-19 vaccination history to intake forms and recommending follow-up ultrasound for MRI-detected axillary lymphadenopathy, can aid in appropriate management and monitoring.

AMERICAN JOURNAL OF ROENTGENOLOGY (2021)

Add to Collection

Editorial Material Oncology

The ESMO Call to Action on COVID-19 vaccinations and patients with cancer: Vaccinate. Monitor. Educate

M. C. Garassino et al.

ANNALS OF ONCOLOGY (2021)

Add to Collection

Article Infectious Diseases

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial

Yanjun Zhang et al.

Summary: This study investigated the safety, tolerability, and immunogenicity of the COVID-19 vaccine candidate CoronaVac, and found that the 3 μg dose showed higher seroconversion rates in the phase 2 trial.

LANCET INFECTIOUS DISEASES (2021)

Add to Collection

Editorial Material Oncology

SARS-CoV-2 vaccination and phase 1 cancer clinical trials

Timothy A. Yap et al.

LANCET ONCOLOGY (2021)

Add to Collection

Letter Biochemistry & Molecular Biology

COVID-19 vaccination: the VOICE for patients with cancer

Astrid A. M. van der Veldt et al.

NATURE MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Association of Social and Demographic Factors With COVID-19 Incidence and Death Rates in the US

Monita Karmakar et al.

Summary: This study found an association between county-level sociodemographic risk factors and COVID-19 incidence and mortality in the US. The Social Vulnerability Index was significantly correlated with both COVID-19 outcomes, suggesting that addressing social vulnerabilities and their root causes is essential to combat the disparities in the burden of the pandemic.

JAMA NETWORK OPEN (2021)

Add to Collection

Article Medicine, General & Internal

Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area

Safiya Richardson et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)

Add to Collection

Article Medicine, General & Internal

Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study

Nicole M. Kuderer et al.

LANCET (2020)

Add to Collection

Letter Medicine, General & Internal

Association of the Coronavirus Disease 2019 (COVID-19) Outbreak With Enrollment in Cancer Clinical Trials

Joseph M. Unger et al.

JAMA NETWORK OPEN (2020)

Add to Collection

Article Medicine, General & Internal

Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia

Denis Y. Logunov et al.

LANCET (2020)

Add to Collection

Letter Oncology

COVID-19 and Cancer: Lessons From a Pooled Meta-Analysis

Aakash Desai et al.

JCO GLOBAL ONCOLOGY (2020)

Add to Collection

Article Oncology

Optimal Timing of Influenza Vaccination During 3-Week Cytotoxic Chemotherapy Cycles

Bhumsuk Keam et al.

CANCER (2017)

Add to Collection

Review Immunology

Drug Hypersensitivity and Anaphylaxis in Cancer and Chronic Inflammatory Diseases: The Role of Desensitizations

Mariana Castells

FRONTIERS IN IMMUNOLOGY (2017)

Add to Collection

Article Immunology

2013 IDSA Clinical Practice Guideline for Vaccination of the Immunocompromised Host

Lorry G. Rubin et al.

CLINICAL INFECTIOUS DISEASES (2014)

Add to Collection

© Peeref 2019-2024. All rights reserved.